Wayde McMillan Biography and Net Worth

CFO of Insulet

Wayde D. McMillan serves as Chief Financial Officer, Executive Vice President, Treasurer of the Company. Mr. McMillan has served as our Executive Vice President, Chief Financial Officer and Treasurer since March 2019. From January 2015 to March 2019, he was Chief Financial Officer and Vice President of Finance of the Minimally Invasive Therapies Group at Medtronic plc. From November 2006 to January 2015, prior to Medtronic’s acquisition of Covidien plc, Mr. McMillan held a variety of leadership positions at Covidien, including Chief Financial Officer and Vice President of Finance of the Medical Devices Group & U.S., Chief Financial Officer and Vice President of Finance of the Surgical Solutions Business Unit, and Vice President Finance and Controller of the Respiratory and Monitoring Solutions Business Unit. Mr. McMillan started his career in accounting, audit, financial analysis and investor relations positions at various institutions. Mr. McMillan earned his Bachelor of Science in Business Administration from Merrimack College and a Master of Business Administration from the Bentley University McCallum Graduate School of Business.

What is Wayde D. McMillan's net worth?: The estimated net worth of Wayde D. McMillan is at least $5.73 million as of July 3rd, 2023. Mr. McMillan owns 21,477 shares of Insulet stock worth more than $5,725,339 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. McMillan may own. Learn More about Wayde D. McMillan's net worth.
How do I contact Wayde D. McMillan?: The corporate mailing address for Mr. McMillan and other Insulet executives is 100 NAGOG PARK, ACTON MA, 01720. Insulet can also be reached via phone at (978) 600-7000 and via email at [email protected]. Learn More on Wayde D. McMillan's contact information.
Has Wayde D. McMillan been buying or selling shares of Insulet?: Wayde D. McMillan has not been actively trading shares of Insulet over the course of the past ninety days. Most recently, Wayde D. Mcmillan sold 1,388 shares of the business's stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $282.94, for a transaction totalling $392,720.72. Following the completion of the sale, the chief financial officer now directly owns 21,477 shares of the company's stock, valued at $6,076,702.38. Learn More on Wayde D. McMillan's trading history.
Who are Insulet's active insiders?: Insulet's insider roster includes Charles Alpuche (COO), Eric Benjamin (SVP), Luciana Borio (Director), Bret Christensen (EVP), Sally Crawford (Director), John Fallon (Director), Mark Field (SVP and Chief Technology Officer), James Hollingshead (CEO), Dan Manea (SVP), Wayde McMillan (CFO), Shacey Petrovic (CEO), Timothy Scannell (Director), Prem Singh (SVP), and Michael Spears (SVP). Learn More on Insulet's active insiders.
Are insiders buying or selling shares of Insulet?: In the last twelve months, insiders at the medical instruments supplier sold shares 5 times. They sold a total of 25,540 shares worth more than $4,527,624.61. The most recent insider tranaction occured on June, 14th when SVP Mark N Field sold 1,500 shares worth more than $299,940.00. Insiders at Insulet own 0.5% of the company. Learn More about insider trades at Insulet.
Information on this page was last updated on 6/14/2024.

Wayde D. McMillan Insider Trading History at Insulet

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/3/2023	Sell	1,388	$282.94	$392,720.72	21,477
4/3/2023	Sell	1,255	$318.31	$399,479.05	22,865
4/1/2022	Sell	1,455	$275.60	$400,998.00	21,354

Wayde D. McMillan Buying and Selling Activity at Insulet

Insulet Company Overview

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Today's Range

Now: $266.58

$260.63

$267.05

50 Day Range

MA: $240.09

$227.79

$275.70

2 Week Range

Now: $266.58

$160.19

$279.40

Volume

504,270 shs

Average Volume

606,420 shs

Market Capitalization

$18.70 billion

P/E Ratio

45.65

Dividend Yield

N/A

Beta

1.22

📉 Warning: Market Crash Predicted - Secure Your Savings

From Behind the Markets | Ad

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>